High costs serve as barrier to care High out-of-pocket costs for people without insurance coverage remain a key factor in determining who can benefit from GLP-1 medications and who cannot, said Tracy Svenyach, PhD, director of policy strategy and alliance at the Obesity Action Coalition
Common, then rare: the same list, sorted by likelihood Real-world reporting databases echo the trial pattern, with nausea and constipation leading the list (Liu and colleagues, pharmacovigilance analysis, Frontiers in Endocrinology , 2022)
Itching or mild rash: Some patients experience localised itching, which is usually self-limiting
33 , 791803.e7 (2021)
Our team is excited to be a part of your weight loss journey
Dietary fibre is fundamental to maintaining regular bowel function